Mixed trend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 28 · below the Ichimoku cloud · RSI 55 · MACD above its signal
| 0.0500 | 52-week high | +7042.86% |
| 0.003000 | Previous month high | +328.57% |
| 0.000700 | Price now | |
| 0.000700 | R3 (classic) | −0.00% |
| 0.000700 | R2 (classic) | −0.00% |
| 0.000700 | R1 (classic) | −0.00% |
| 0.000700 | Pivot | −0.00% |
| 0.000700 | S1 (classic) | −0.00% |
| 0.000700 | S2 (classic) | −0.00% |
| 0.000700 | S3 (classic) | −0.00% |
| 0.000700 | Previous day high | −0.00% |
| 0.000700 | Previous day low | −0.00% |
| 0.000600 | Previous week high | −14.29% |
| 0.000100 | Previous week low | −85.71% |
| 0.000100 | Previous month low | −85.71% |
| 0.000100 | 52-week low | −85.71% |
None of the 29 investors followed here reported a position in IPIX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a IPIX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for IPIX.
TimeframesDown on the monthly, mixed on the daily and weekly.
bouncing over the 21 EMA
bouncing over the 21 EMA
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.0 | -22.2 | 0.0 | -85.7 | 300.0 | -25.0 | 566.7 | -25.0 | -26.7 | -36.4 | −30.0% | ||
| 2025 | 0.0 | 0.0 | 100.0 | 100.0 | -75.0 | 0.0 | 200.0 | 566.7 | 50.0 | -66.7 | -30.0 | 42.9 | +900.0% |
| 2024 | 54.6 | -6.7 | 103.6 | -89.5 | 0.0 | -20.0 | -16.7 | -70.0 | -33.3 | 100.0 | -75.0 | 0.0 | −97.9% |
| 2023 | 12.4 | -29.7 | 33.3 | -4.2 | -8.7 | 14.4 | -14.5 | -7.0 | -24.5 | -33.3 | -37.5 | -3.0 | −74.5% |
| 2022 | 1.6 | -18.6 | -12.4 | -25.7 | 1.1 | 11.5 | 29.0 | 1.3 | -17.5 | -13.8 | -25.5 | -11.4 | −62.8% |
| 2021 | 39.4 | 33.3 | -19.5 | -21.0 | 4.3 | -1.6 | 25.3 | 7.9 | -15.4 | 23.7 | -78.0 | -23.7 | −71.2% |
| 2020 | 38.7 | 36.7 | 19.8 | 7.8 | 19.7 | 138.2 | -44.4 | -0.2 | -7.8 | 3.4 | -20.5 | 4.4 | +206.0% |
| 2019 | 57.2 | -13.3 | -17.6 | 35.5 | 69.0 | -23.7 | -2.2 | -27.8 | -20.5 | -11.4 | -20.4 | -21.6 | −39.2% |
| 2018 | 4.3 | -15.1 | -16.1 | -16.6 | -0.6 | 36.9 | -19.2 | -16.6 | -49.2 | -34.2 | 1.5 | -29.4 | −86.4% |
| 2017 | -14.7 | 1.0 | 0.0 | -25.5 | 22.1 | 5.5 | -11.4 | -17.1 | 3.5 | 2.7 | 0.7 | -7.3 | −39.7% |
| 2016 | -3.8 | -8.6 | 32.9 | 18.3 | -19.0 | -6.7 | -7.9 | 0.8 | 0.0 | -12.0 | 8.4 | -5.7 | −12.8% |
| 2015 | -16.4 | 0.3 | -14.1 | -4.4 | -5.6 | -9.5 | -0.4 | -22.8 | -26.4 | 6.8 | 10.9 | -23.1 | −69.7% |
| 2014 | -5.3 | -2.5 | -15.0 | 14.6 | -10.1 | -1.2 | -1.2 | 24.2 | 47.3 | 10.9 | -5.4 | 38.5 | +110.0% |
| 2013 | 3.8 | -17.4 | 11.5 | -8.0 | 36.0 | -19.2 | 9.0 | -1.0 | -4.7 | -0.5 | -9.9 | 28.2 | +14.2% |
| 2012 | -22.9 | -1.9 | -1.9 | 0.0 | 5.8 | 18.2 | -0.8 | -2.3 | 58.7 | -5.0 | 8.4 | 77.7 | +161.4% |
| 2011 | 42.9 | 60.0 | 165.6 | 5.9 | 0.0 | -18.9 | -5.5 | -52.2 | 30.3 | -25.6 | 123.4 | -2.1 | +400.0% |
| 2010 | -25.0 | 0.0 | 60.0 | -37.5 | 46.7 | 22.7 | 9.3 | -23.7 | 37.8 | -35.5 | -47.5 | -33.3 | −65.0% |
| 2009 | 0.0 | 0.0 | 0.0 | 75.0 | 185.7 | -62.0 | 13.2 | -18.6 | 14.3 | 30.0 | -1.9 | -21.6 | +100.0% |
| 2008 | 0.0 | 280.0 | 0.0 | 0.0 | -47.9 | -42.4 | 0.0 | -33.3 | 34.2 | -60.8 | 0.0 | 0.0 | −60.0% |
| 2007 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
No analyst coverage for this instrument.
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It offers Brilacidin, a immunomodulatory drug candidate with anti-inflammatory and antimicrobial therapeutic applications. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
No recent headlines.